CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of CEL-SCI (NYSE:CVM) in a research note published on Friday. The brokerage issued a sell rating on the stock.

CEL-SCI Stock Performance

Shares of NYSE:CVM opened at $0.22 on Friday. The firm’s 50 day simple moving average is $0.25 and its 200-day simple moving average is $0.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07. CEL-SCI has a one year low of $0.18 and a one year high of $2.22. The firm has a market cap of $18.76 million, a PE ratio of -0.46 and a beta of 0.50.

Hedge Funds Weigh In On CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Thoroughbred Financial Services LLC increased its holdings in CEL-SCI Co. (NYSE:CVM) by 40.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 191,661 shares of the company’s stock after acquiring an additional 54,900 shares during the quarter. Thoroughbred Financial Services LLC owned approximately 0.26% of CEL-SCI worth $76,000 as of its most recent SEC filing. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.